COVID-19 News

The VA Research Enterprise: A Platform for National Partnerships Toward Evidence Building and Scientific Innovation

Author and Disclosure Information

 

References

Future Directions

The VA continues to work for veterans by emphasizing its strategic goals and strengths in clinical, data science, and other pioneering activities at an enterprise level to provide the highest quality evidence for care. These capabilities perpetuate a scientific and learning environment that also builds toward the future by giving junior investigators and others opportunities to work within a national health care setting. In turn, this provides a more focused perspective on endeavors that align with the VA mission through ORD-supported career development, merit review (independent investigator submissions), and CSP.19 Preclinical, health services, genomic, and implementation research were given insights into more effective operational and methodological partnerships to help inform the health care system. The pandemic also served to strengthen our ability to mobilize and prepare even faster for emergencies and other potential disease outbreaks, including newer pandemic concerns (eg, mpox, Ebola) from research and public health perspectives.

Conclusions

Throughout its 100-year history, VA Research has been a critical, enduring institution within the national medical landscape. The ability to collaborate with partners has helped us to design and create even better processes, optimize and maximize our infrastructure, and learn more about common research interests that can be even more responsive to national health care needs. As an enterprise, VA Research also aims to continually learn and expand on these valuable lessons gained from internal, interagency, and industry collaborations to effectively meet and exceed our mission to serve our veterans.

Acknowledgments

The authors acknowledge Daphne Swancutt for her contribution as copywriter for this manuscript.

Pages

Recommended Reading

COVID booster may transiently raise glucose levels in T1D
Federal Practitioner
Paxlovid and Lagevrio benefit COVID outpatients in Omicron era
Federal Practitioner
Creatine may improve key long COVID symptoms: Small study
Federal Practitioner
Paxlovid weaker against current COVID-19 variants
Federal Practitioner
Study: Antiviral med linked to COVID mutations that can spread
Federal Practitioner
Study: Unexpected vaginal bleeding rises after COVID vaccination
Federal Practitioner
Don’t fear POTS: Tips for diagnosis and treatment
Federal Practitioner
COVID, no matter the severity, linked with urologic effects in men
Federal Practitioner
Foreword: VA Research and COVID-19
Federal Practitioner
Introduction
Federal Practitioner